INS

COMPANY DESK

AstraZeneca

AZN · XSTO

Health Care

AstraZeneca PLCISIN GB0009895292LEI PY6ZZQWO2IZFZC3IOL08IR site
Show on capital radar →Export evidence pack
Sources healthyNewest data 4m ago

corporate-events

Event-driven volatility

1.25 · 30d · 2m ago

high confidence

composite

Positive activity cluster

0.69 · multi-window · 2m ago

high confidence

narrative-velocity

Insufficient data

0.00 · 72h · 2m ago

low confidence

market-activity

Positive activity cluster

0.53 · 5/20/60d · 2m ago

high confidence

insider-activity

Insufficient data

0.00 · 90d · 2m ago

low confidence

Price & volume

AZN · daily bars · evidence markers

Public source
Loading price chart…

TIMELINE · FULL WINDOW

Price and event windows provide context only and do not establish causation.

Market data source: Free OHLC fallback (Yahoo Finance) — unofficial Yahoo OHLC fallback (low credibility).

Company brief

AI-generated from ingested evidence only

No narrative generated yet.

The AI enrichment stage synthesizes a brief once enough source documents exist for this company.

What changed

40 events

other—

AstraZeneca: Datroway[ ]approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy

AstraZenecaIssuer IR via MFN (press rooms)Public sourcelow confidenceSource
other—

AstraZeneca: Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant

AstraZenecaIssuer IR via MFN (press rooms)Public sourcelow confidenceSource
other—

AstraZeneca: Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

AstraZenecaIssuer IR via MFN (press rooms)Public sourcelow confidenceSource
Earnings—

Resultat för AstraZeneca: Första halvåret samt andra kvartalet 2026

AstraZenecaIssuer IR via MFN (press rooms)Public sourcelow confidenceSource
Earnings—

AstraZeneca: Half-year Financial Report

AstraZenecaIssuer IR via MFN (press rooms)Public sourcelow confidenceSource
other—

AstraZeneca: Enhertu plus pertuzumab recommended for approval in the EU by CHMP as 1st-line treatment for patients with HER2-positive metastatic breast cancer

AstraZenecaIssuer IR via MFN (press rooms)Public sourcelow confidenceSource
other—

AstraZeneca: Trixeo recommended for approval in the EU by CHMP for the maintenance treatment of asthma

AstraZenecaIssuer IR via MFN (press rooms)Public sourcelow confidenceSource
other—

AstraZeneca: Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1st-line advanced ER-positive breast cancer

AstraZenecaIssuer IR via MFN (press rooms)Public sourcelow confidenceSource
other—

AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical

AstraZenecaIssuer IR via MFN (press rooms)Public sourcelow confidenceSource
other—

AstraZeneca: Update on CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathy

AstraZenecaIssuer IR via MFN (press rooms)Public sourcelow confidenceSource
other—

Efzimfotase alfa showed bone health improvements in treatment-naïve paediatric patients with hypophosphatasia: median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase 3 trial

AstraZenecaIssuer IR via MFN (press rooms)Public sourcelow confidenceSource
other—

AstraZeneca: Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours

AstraZenecaIssuer IR via MFN (press rooms)Public sourcelow confidenceSource
other—

AstraZeneca: Datroway[ ]recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy

AstraZenecaIssuer IR via MFN (press rooms)Public sourcelow confidenceSource
other—

AstraZeneca: Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy

AstraZenecaIssuer IR via MFN (press rooms)Public sourcelow confidenceSource
other—

AstraZeneca: Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

AstraZenecaIssuer IR via MFN (press rooms)Public sourcelow confidenceSource

Capital structure (FI)

Blankning + Flaggning aggregates

RADAR →

No disclosed shorts or flaggningar linked yet.

Significant FI Blankning positions and major-holding notices appear here when resolved to this issuer.

Reported insider transactions

FI PDMR register · trend vs share-price window

No reported insider transactions.

Announcements & filings

  • AstraZeneca: Datroway[ ]approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy

    Announcement10d agoIssuer IR via MFN (press rooms)Source

  • AstraZeneca: Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant

    Announcement14d agoIssuer IR via MFN (press rooms)Source

  • AstraZeneca: Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

    Announcement14d agoIssuer IR via MFN (press rooms)Source

  • Resultat för AstraZeneca: Första halvåret samt andra kvartalet 2026

    interim-report14d agoIssuer IR via MFN (press rooms)Source

  • AstraZeneca: Half-year Financial Report

    interim-report14d agoIssuer IR via MFN (press rooms)Source

  • AstraZeneca: Enhertu plus pertuzumab recommended for approval in the EU by CHMP as 1st-line treatment for patients with HER2-positive metastatic breast cancer

    Announcement17d agoIssuer IR via MFN (press rooms)Source

  • AstraZeneca: Trixeo recommended for approval in the EU by CHMP for the maintenance treatment of asthma

    Announcement17d agoIssuer IR via MFN (press rooms)Source

  • AstraZeneca: Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1st-line advanced ER-positive breast cancer

    Announcement18d agoIssuer IR via MFN (press rooms)Source

  • AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical

    Announcement27d agoIssuer IR via MFN (press rooms)Source

  • AstraZeneca: Update on CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathy

    Announcement2026-07-09Issuer IR via MFN (press rooms)Source

  • Efzimfotase alfa showed bone health improvements in treatment-naïve paediatric patients with hypophosphatasia: median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase 3 trial

    Announcement2026-06-29Issuer IR via MFN (press rooms)Source

  • AstraZeneca: Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours

    Announcement2026-06-29Issuer IR via MFN (press rooms)Source

  • AstraZeneca: Datroway[ ]recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy

    Announcement2026-06-26Issuer IR via MFN (press rooms)Source

  • AstraZeneca: Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy

    Announcement2026-06-15Issuer IR via MFN (press rooms)Source

  • AstraZeneca: Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

    Announcement2026-06-15Issuer IR via MFN (press rooms)Source

  • Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca's cardiometabolic and kidney portfolio

    Announcement2026-06-08Issuer IR via MFN (press rooms)Source

  • AstraZeneca: Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo in adults with immunoglobulin A nephropathy at 34 weeks in I CAN Phase III trial

    Announcement2026-06-06Issuer IR via MFN (press rooms)Source

  • AstraZeneca: Camizestrant combination delayed time to first progression by 55% and to second progression by 37% in patients with advanced HR-positive breast cancer with an emergent ESR1 mutation in SERENA-6 trial

    Announcement2026-06-02Issuer IR via MFN (press rooms)Source

  • AstraZeneca: Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial

    Announcement2026-06-01Issuer IR via MFN (press rooms)Source

  • AstraZeneca: CARES Phase III clinical programme did not meet primary endpoint in overall AL amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa AL amyloidosis

    Announcement2026-05-29Issuer IR via MFN (press rooms)Source

  • AstraZeneca: Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

    Announcement2026-05-29Issuer IR via MFN (press rooms)Source

  • AstraZeneca: US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data

    Announcement2026-05-27Issuer IR via MFN (press rooms)Source

  • AstraZeneca: Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

    Announcement2026-05-22Issuer IR via MFN (press rooms)Source

  • AstraZeneca: Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours

    Announcement2026-05-22Issuer IR via MFN (press rooms)Source

  • AstraZeneca: Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive breast cancer

    Announcement2026-05-22Issuer IR via MFN (press rooms)Source

Key people

No people linked yet.

People are linked from FI PDMR reports and announcements via entity resolution.

Themes

No theme exposure detected.

Related companies

Explore

Open in company explorer →All intelligence for AstraZeneca →